RHYTHM PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $26.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $26.06M, a 64.08% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $23.10M, a 79.59% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $18.81M, a 70.98% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $15.88M, a 53.31% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $66.82M, a 68.38% increase from fiscal 2024.
- RHYTHM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $39.68M, a 21.90% increase from fiscal 2023.
- RHYTHM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $32.55M, a 64.15% increase from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $19.83M, a 4.68% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.06M 10-Q · filed 2026-08-04 | $49.16M derived: sum of 2 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $23.10M 10-Q · filed 2026-08-04 | |||
| 2025-12-31 | $66.82M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $18.81M 10-Q · filed 2025-11-04 | $34.69M derived: sum of 2 quarters · filed 2026-08-04 | $47.55M derived: sum of 3 quarters · filed 2026-08-04 | |
| 2025-06-30 | $15.88M 10-Q · filed 2026-08-04 | $28.74M derived: sum of 2 quarters · filed 2026-08-04 | ||
| 2025-03-31 | $12.86M 10-Q · filed 2026-08-04 | |||
| 2024-12-31 | $39.68M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $11.00M 10-Q · filed 2025-11-04 | $21.36M derived: sum of 2 quarters · filed 2025-11-04 | $29.13M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $10.36M 10-Q · filed 2025-11-04 | $18.13M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $7.77M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $32.55M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $8.61M 10-Q · filed 2024-11-06 | $17.50M derived: sum of 2 quarters · filed 2024-11-06 | $23.88M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $8.89M 10-Q · filed 2024-11-06 | $15.27M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $6.38M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $19.83M 10-K · filed 2025-02-28 | |||
| 2022-09-30 | $4.80M 10-Q · filed 2023-11-08 | $9.93M derived: sum of 2 quarters · filed 2023-11-08 | $14.54M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $5.14M 10-Q · filed 2023-11-08 | $9.75M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $4.61M 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $20.80M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $5.27M 10-Q · filed 2022-11-08 | $10.94M derived: sum of 2 quarters · filed 2022-11-08 | $16.13M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $5.67M 10-Q · filed 2022-11-08 | $10.86M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $5.19M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $17.45M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $4.70M 10-Q · filed 2021-11-02 | $7.72M derived: sum of 2 quarters · filed 2021-11-02 | $13.20M derived: sum of 3 quarters · filed 2021-11-02 | |
| 2020-06-30 | $3.03M 10-Q · filed 2021-11-02 | $8.50M derived: sum of 2 quarters · filed 2021-11-02 | ||
| 2020-03-31 | $5.47M 10-Q · filed 2021-11-02 | |||
| 2019-12-31 | $11.88M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $3.04M 10-Q · filed 2020-11-02 | $6.31M derived: sum of 2 quarters · filed 2020-11-02 | $8.95M derived: sum of 3 quarters · filed 2020-11-02 | |
| 2019-06-30 | $3.27M 10-Q · filed 2020-11-02 | $5.92M derived: sum of 2 quarters · filed 2020-11-02 | ||
| 2019-03-31 | $2.64M 10-Q · filed 2020-11-02 | |||
| 2018-12-31 | $5.43M 10-Q · filed 2019-05-03 | $6.39M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $1.89M 10-Q · filed 2019-11-01 | $3.41M derived: sum of 2 quarters · filed 2019-11-01 | $4.37M derived: sum of 3 quarters · filed 2019-11-01 | $5.08M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $1.52M 10-Q · filed 2019-11-01 | $2.47M derived: sum of 2 quarters · filed 2019-11-01 | $3.18M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2018-03-31 | $958.00K 10-Q · filed 2019-11-01 | $1.67M derived: sum of 2 quarters · filed 2020-03-02 | ||
| 2017-12-31 | $709.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $2.28M 10-K · filed 2020-03-02 | ||
| 2017-09-30 | $1.57M 10-Q · filed 2017-11-14 | |||
| 2016-12-31 | $1.17M 10-K · filed 2019-03-08 | |||
| 2015-12-31 | $298.00K 8-K · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |